Ovid Therapeutics (OVID) Short-term Investments (2018 - 2026)

Ovid Therapeutics (OVID) has reported Short-term Investments for 8 consecutive years, with $105.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Short-term Investments rose 966.17% year-over-year to $105.9 million; the trailing twelve-month figure through Jun 2026 stood at $105.9 million (up 966.17% YoY), and the FY2025 full-year result was $56.5 million, up 110.96% from the prior year.
• Short-term Investments climbed to $105.9 million in Q2 2026 per OVID's latest filing, from $61.5 million in the prior quarter.
• Across five years, Short-term Investments topped out at $105.9 million in Q2 2026 and bottomed at $5.0 million in Q3 2025.
• Historically, Short-term Investments has averaged $51.4 million across 5 years, with a median of $54.7 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Short-term Investments sank 89.53% in 2025, then surged 966.17% in 2026.
• Over 5 years, Short-term Investments stood at $84.1 million in 2022, then slipped by 6.35% to $78.8 million in 2023, then plunged by 66.02% to $26.8 million in 2024, then surged by 110.96% to $56.5 million in 2025, then surged by 87.48% to $105.9 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $105.9 million, $61.5 million, and $56.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.